Abstract:This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and prodromal Alzheimer's disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, and indications for disease management. The core clinical features of dementia with Lewy bodies (DLB)-parkinsonism, complex visual hallucinations, cognitive fluctuations, and REM sleep behaviour disorder are common prodromal symptoms. Supportive clinical features of pDLB include severe neuroleptic sensitivity, as well as autonomic and neuropsychiatric symptoms. The neuropsychological profile in mild cognitive impairment attributable to Lewy body pathology (MCI-LB) tends to include impairment in visuospatial skills and executive functioning, distinguishing it from MCI due to AD, which typically presents with impairment in memory. pDLB may present with cognitive impairment, psychiatric symptoms, and/or recurrent episodes of delirium, indicating that it is not necessarily synonymous with MCI-LB. Imaging, fluid and other biomarkers may play a crucial role in differentiating pDLB from pAD. The current MCI-LB criteria recognise low dopamine transporter uptake using positron emission tomography or single photon emission computed tomography (SPECT), loss of REM atonia on polysomnography, and sympathetic cardiac denervation using meta-iodobenzylguanidine SPECT as indicative biomarkers with slowing of dominant frequency on EEG among others as supportive biomarkers. This review also highlights the emergence of fluid and skin-based biomarkers. There is little research evidence for the treatment of pDLB, but pharmacological and non-pharmacological treatments for DLB may be discussed with patients. Non-pharmacological interventions such as diet, exercise, and cognitive stimulation may provide benefit, while evaluation and management of contributing factors like medications and sleep disturbances are vital. There is a need to expand research across diverse patient populations to address existing disparities in clinical trial participation. In conclusion, an early and accurate diagnosis of pDLB or pAD presents an opportunity for tailored interventions, improved healthcare outcomes, and enhanced quality of life for patients and care partners.

Dementia with Lewy Bodies and Parkinson's Disease-Dementia: Current Perspectives

Parkinson's Disease and Dementia with Lewy Bodies: One and the Same

Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease)

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

Clinical diagnostic criteria for dementia associated with Parkinson's disease

Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology

The Impact of Dementia Development Concurrent with Parkinson's Disease: a New Perspective.

Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias

Clinical analysis of dementia with lewy body

Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians

Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies

Behavioral disorders in dementia with Lewy bodies: old and new knowledge

Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset

The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias

Clinicopathological Heterogeneity of Lewy Body Diseases: The Profound Influence of Comorbid Alzheimer Disease

Clinicopathological Heterogeneity of Lewy Body Diseases: The Profound Influence of Comorbid Alzheimer's Disease

Longitudinal Motor Decline in Dementia with Lewy Bodies, Parkinson Disease Dementia, and Alzheimer's Dementia in a Community Autopsy Cohort

Investigation of the genetic aetiology of Lewy body diseases with and without dementia

Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease

Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design

Clinical features of dementia with lewy bodies in 35 Chinese patients